Essential CNS drug developmentcedited / Edited by Amir Kalali , Sheldon Preskorn , Joseph Kwentus , Stephen M. Stahl
-
| | | Essential CNS drug developmentcedited. |
| x, 207 pages : illustrations ; 24 cm Cambridge medicine. | Machine generated contents note: History of CNS drug development / Sheldon H. Preskorn -- Regulatory issues / Gwen L. Zornberg -- Pre-clinical development / Alan J. Cross and Frank D. Yocca -- Phase I trials: from traditional to newer approaches / Matthew Macaluso, Michael Krams and Sheldon H. Preskorn -- Phase II development and the path to personalized medicine in CNS disease / Douglas E. Feltner and Kenneth R. Evans -- CNS drug development - Phase III / Judith Dunn, Penny Randall and Amir Kalali / Statistics issues relevant to CNS drug development / Craig H. Mallinckrodt, William R. Prucka and Geert Molenberghs -- Clinical trials management at company level / Nuala Murphy -- Clinical trials management at the site level / Joseph Kwentus -- Medical writing for CNS indications / Ginette Nachman -- Dissemination of clinical trial information: multiple audiences, multiple formats / Leslie Citrome -- The importance of treating cognition in schizophrenia and other severe mental illnesses: background, strategies, and findings to date / Philip D. Harvey and Richard S. E. Keefe -- Leveraging disruptive technologies to drive innovation in CNS clinical drug development / Penny Randall, Judith Dunn and Amir Kalali. | ISBN 9780521766067 | .-ISBN 0521766060. | | 1. Central Nervous System Agents - pharmacology 2. Clinical Trials as Topic - methods 3. Drug Evaluation - methods 4. Drug Evaluation, Preclinical - methods.I. Kalali, Amir II. Preskorn, Sheldon III. Kwentus, Joseph IV. Stahl, Stephen M. V. Title VI. Series | | Library : UiTM Shah Alam |
| Accn No. | Item Status | Add Id | Location | SMD | Item Category | 929015 | Shelf | | PERP. PERUBATAN TAR KAMPUS TELUK INTAN(PPTI) | BOOK | RAK TERBUKA (OPEN SHELVES) | 964508 | Shelf | | PERP. PERUBATAN TAR KAMPUS SG. BULOH(PPSB) | BOOK | RAK TERBUKA (MEDICAL SCI) |
|
|
|